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1  | INTRODUC TION
Systemic microvascular dysfunction has been associated with 
increased cardiovascular morbidity1,2 and mortality.3,4 This as-
sociation is potentially being driven by shared underlying patho-
logical events instrumental in both macro and microvascular 
disease. Persistent changes in vascular tone lead to structural 
remodelling. Repeated activation of the vascular endothelium by 
pro-atherogenic insults results in an imbalance in the production 
of vasoactive substances, inflammation, and a pro-thrombotic 
state.5 In combination, these changes compromise the structural 
and functional ability of the microcirculation to compensate for 
fluctuating demands.
It is in the coronary circulation, where up to 80% of overall resis-
tance resides in the microvessels,6 that dysfunction has been most 
convincingly linked to clinically relevant outcomes. The presence of 
 
Received: 7 November 2019  |  Revised: 8 February 2020  |  Accepted: 14 February 2020
DOI: 10.1111/micc.12613  
R E V I E W
The systemic microcirculation in dialysis populations
Jennifer Williams1,2  |   Mark Gilchrist1,2 |   David Strain1,2 |   Donald Fraser3 |   
Angela Shore1,2
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Microcirculation published by John Wiley & Sons Ltd.
Abbreviations: Ach, acetylcholine; eGFR, estimated glomerular filtration rate; NO, nitric oxide; RBC, red blood cell; SDF, side-stream darkfield; SNP, sodium nitroprusside.
1Diabetes and Vascular Medicine Research 
Centre, Institute of Biomedical and Clinical 
Science, University of Exeter Medical 
School, Exeter, UK
2NIHR Exeter Clinical Research Facility, 
Royal Devon and Exeter Foundation NHS 
Trust, Exeter, UK
3Wales Kidney Research Unit, Cardiff 
University, Cardiff, UK
Correspondence
Angela Shore, Diabetes and Vascular 
Research Centre, NIHR Exeter clinical 
research facility, Royal Devon and Exeter 
Foundation NHS Trust, Barrack Road, Exeter 
EX2 5DW, UK.
Email: a.c.shore@exeter.ac.uk
Funding information
Jennifer Williams is funded by a Kidney 
Research UK Training Fellowship 
TF_013_20151127.
Abstract
In a rapidly expanding population of patients with chronic kidney disease, including 
2 million people requiring renal replacement therapy, cardiovascular mortality is 15 
times greater than the general population. In addition to traditional cardiovascular 
risk factors, more poorly defined risks related to uremia and its treatments appear to 
contribute to this exaggerated risk. In this context, the microcirculation may play an 
important early role in cardiovascular disease associated with chronic kidney disease. 
Experimentally, the uremic environment and dialysis have been linked to multiple 
pathways causing microvascular dysfunction. Coronary microvascular dysfunction is 
reflected in remote and more easily studied vascular beds such as the skin. There is 
increasing evidence for a correlation between systemic microvascular dysfunction 
and adverse cardiovascular outcomes. Systemic microcirculatory changes have not 
been extensively investigated across the spectrum of chronic kidney disease. Recent 
advances in non-invasive techniques studying the microcirculation in vivo in man are 
increasing the data available particularly in patients on hemodialysis. Here, we review 
current knowledge of the systemic microcirculation in dialysis populations, explore 
whether non-invasive techniques to study its function could be used to detect early 
stage cardiovascular disease, address challenges faced in studying this patient cohort 
and identify potential future avenues for research.
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coronary microvascular and endothelial dysfunction not only pre-
dicts subsequent cardiovascular events,7-9 but themselves consti-
tute the first stage of atherosclerotic coronary artery disease.10,11 
Up to 40% of patients referred for angiography following “typical 
cardiac chest pain” are found to have normal epicardial coronary ar-
teries.12 These patients can be assumed to have a combination of 
functional and structural coronary microvascular disease contribut-
ing to abnormal myocardial perfusion.
This impairment of coronary microvascular structure and func-
tion is reflected in concurrent changes in remote and more easily 
studied vascular beds. For example, significant reductions in dermal 
capillary numbers have been demonstrated in patients with “typical 
cardiac chest pain” despite normal coronary arteries.13 Peripheral 
microvascular dysfunction has, therefore, been used as a surrogate 
for dysfunction of the coronary microcirculation.
There are a growing number of novel methods being utilized to 
study the structure and function of the systemic microcirculation in 
vivo in multiple patient cohorts, including those with chronic kidney 
disease.14
2  | WHY STUDY THE MICROCIRCUL ATION 
IN END -STAGE RENAL DISE A SE?
The global prevalence of chronic renal disease is upwards of 
13%15 and more than 2 million people worldwide are depend-
ent on renal replacement therapies.16 In this population, rates of 
cardiovascular mortality are 15 times those of the general popu-
lation.17 Although traditional cardiovascular risk factors are prev-
alent within the dialysis population, their presence alone does not 
fully account for this exaggerated risk.18 In this context, systemic 
microcirculatory dysfunction may be a significant contributor to 
cardiovascular burden.
Patients with end-stage renal disease who are on dialysis are 
at significant risk for systemic microvascular dysfunction. Uremia 
is associated with endothelial cell activation,19 impaired endothe-
lial repair,20 oxidative stress,21 and impaired NO bioavailability. 
Additionally, these patients exist in a state of chronic inflamma-
tion.22 Levels of inflammatory mediators such as Interleukin-6 and 
tumor necrosis factor are strongly correlated with eGFR,23 both 
are associated with endothelial dysfunction.24,25 Other dialysis 
specific risk factors include repeated myocardial stunning and 
hemodynamic perturbation of vascular beds26 during hemodialy-
sis and exposure to non-physiological dialysis fluids in peritoneal 
dialysis.26
Multiple studies have demonstrated links between surrogate 
markers of endothelial dysfunction and chronic renal disease. These 
include; circulating endothelial surface layer components,27 markers 
of inflammation and amino acids released by the endothelial cells 
in response to damage,28,29 peptides known to inhibit pro-athero-
genic changes30 and endothelial dysfunction as measured in larger 
vessels.31
3  | THE SYSTEMIC MICROCIRCUL ATION 
IN DIALYSIS PATIENTS
Techniques that directly and non-invasively study in vivo alterations 
in microvascular structure32,33 and function28,34-36 are increasingly 
being used to expand our knowledge of the relationship between 
chronic renal disease and microcirculatory dysfunction. Perturbation 
of microvascular function in patients with chronic renal disease has 
been reproducibly demonstrated in different vascular beds, includ-
ing skin,28,36,37 sublingual,27,32,38 and coronary.39
3.1 | Cutaneous microcirculation
The cutaneous microcirculation, the most easily accessible vascu-
lar bed, has been of interest in patients on dialysis since histological 
alterations were first demonstrated in these patients in the 1980s. 
Skin biopsies from hemodialysis patients without known macrovas-
cular disease or diabetes demonstrated thickening of the basement 
membrane, endothelial activation, and chronic inflammatory cell 
infiltrates in cutaneous capillaries.40 The extent of these changes 
correlated with the length of time these patients had been on he-
modialysis.41 In vivo the nail-fold capillary bed is easily visualized mi-
croscopically. Morphological changes here have also been correlated 
with duration of dialysis.42 Reduction in capillary numbers is impor-
tant as it reduces the surface area available for exchange, jeopardiz-
ing tissue health. Capillary rarefaction has been demonstrated in the 
nail-fold capillaries of pediatric hemodialysis patients33 compared 
with healthy, “height-age” matched controls. The pediatric popula-
tion is interesting to study with regards the microcirculation as un-
like their adult counterparts, they often have a single renal limited 
pathology. This helps to differentiate microcirculatory pathology 
attributable to uremia and its treatments from that attributable to 
other systemic pathologies, for example, diabetes. This finding has 
been replicated in adult hemodialysis cohorts43,44 well matched for 
age, blood pressure, and BMI with healthy controls.
Due to its role in temperature regulation, human skin has a 
high vasodilatory reserve and can change its flow more than a hun-
dred-fold in response to metabolic, thermal, and pharmacologic 
stimuli. Relative changes in skin blood flow can be easily and non-in-
vasively measured using laser Doppler based techniques45 (Figure 1). 
Even in the resting state, oscillations in microvascular flow are mod-
ulated by multiple physiological factors. Spectral analysis can be 
used to sub-divide laser Doppler acquired recordings according to 
their frequency into those representing; endothelial activity, sympa-
thetic activity, vascular myogenic activity, respiratory activity, and 
heart activity.14 Reports of baseline skin blood flow in dialysis pa-
tients did not initially seem to be significantly different to healthy 
controls.28,34,46-48 However, when examined in more detail subtle 
differences were apparent. Although the averaged flux was not dif-
ferent, “hot spots” or distinct spots of high perfusion were reduced 
and significant impairments were noted in the frequency domains 
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corresponding to endothelial, sympathetic, and cardiac activity in 
dialysis patients compared with controls.36
Maximal vasodilation of skin blood vessels can be achieved by lo-
calized heating to between 42 and 44°C.49 A reactive hyperemia can 
also be provoked by a brief period of arterial occlusion50 (Figure 2). 
Impairments in the maximal vasodilatory response to heating36,46 
and maximal post-occlusive flow28,36 have been reported in hemo-
dialysis patients compared with healthy controls.
In their study of 63 hemodialysis patients and 33 healthy con-
trols, Stewart and colleagues36 reported a delay in the maximal va-
sodilatory response to heating in the dialysis patients compared with 
controls. However, they were only able to demonstrate a significant 
reduction in the size of the maximal post-occlusive flow compared 
with controls in those hemodialysis patients with known diabetes 
and cardiovascular disease, not the cohort as a whole. A smaller 
study (16 hemodialysis patients versus 16 controls),28 wherein, all 
participants were “free of concomitant diseases causing alterations 
in endothelium-dependant vasomotion,” did report a reduction in 
maximal post-occlusive flow in the dialysis cohort compared with 
controls. As would be expected, their dialysis group was significantly 
more hypertensive than their healthy controls and given that even 
borderline hypertension effects the microcirculation this may have 
contributed to the microvascular dysfunction observed.
More direct interrogation of this apparent reduction in microvas-
cular function can be achieved by combining laser Doppler measure-
ments with iontophoretic application of vasoactive substances51 
(Figure 3) to investigate which discreet areas of microvascular func-
tion are impaired. Impairments of both endothelial-dependant and 
-independent responses have been demonstrated in hemodialysis 
patients compared with both age, sex, and BMI-matched healthy 
controls28,34 and pre-dialysis chronic renal disease patients with 
comparable cardiovascular burden.52
3.2 | Sublingual microcirculation
More recently, SDF imaging has allowed for direct visualization of 
flow in other vascular beds with a mucosal covering. The most com-
monly studied is the sublingual bed53,54 (Figures 4 and 5). To date 
the only publish study using SDF to examine chronic changes in 
F I G U R E  1   Schematic representation of 
the principles of Laser Doppler measured 
flux. Laser Doppler technology measures 
blood flow in the microcirculation 
to a tissue depth of typically 1 mm. 
Measurements are based on the Doppler 
principle whereby monochromatic light 
changes wavelength when it is reflected 
by moving objects, in this case RBCs. The 
magnitude and frequency of the changes 
in wavelength are related to the number 
and velocity of the moving cells, termed 
RBC flux47
F I G U R E  2   Representative laser 
Doppler trace obtained before, during, 
and after a brief period of arterial 
occlusion. A reactive hyperemia can 
be induced by a brief period of arterial 
occlusion using a cuff placed around the 
upper arm or leg. This response takes 
the form of a post-ischemic flow initially 
many times faster than normal followed 
by exponential decay to baseline.54 This 
is a complex response which remains 
incompletely understood; however, NO 
appears to play only a minor role
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sublingual vessel density and flow in dialysis patients,32 reported a 
reduction in total and perfused vessel density plus increased ves-
sel flow heterogeneity compared with controls. This was particularly 
pronounced in the very small vessels (diameter < 20 µm).32
Assessment of the sublingual circulation also provides an oppor-
tunity to non-invasively assess another component of the vascular 
system, the glycocalyx. The glycocalyx covers the luminal surface 
of endothelial cells. It is a negatively charged network of proteogly-
cans, glycosaminoglycans, and plasma constituents, which acts as an 
interface between the blood and the vascular wall. The glycocalyx 
has important regulatory and protective roles including, regulat-
ing vascular wall permeability, mechano-transduction, and inhibit-
ing leukocyte adhesion. It is susceptible to damage from oxidative 
stress, which may arise from inflammation, ischemia, hyperglycemia, 
or other causes.55 Due to its delicate nature, study of the glycocalyx 
is challenging. Historical approaches have included measurement of 
total volume using tracers, and measuring shed glycocalyx compo-
nents in plasma. Side-stream darkfield-acquired images (Figure 5) 
can now be combined with Glycocheck© software to analyze spa-
tial and temporal variations in erythrocyte column width within the 
microvasculature.56 When the cell-impermeable glycocalyx is dam-
aged, circulating red cells can travel closer to the endothelium. Using 
this approach, loss of glycocalyx barrier properties has been demon-
strated in a mixed cohort of hemodialysis and peritoneal dialysis pa-
tients27 and has been found to associate with diminished eGFR and 
with increased circulating levels of shed endothelial surface layer 
components syndecan-1 and thrombomodulin.38
3.3 | Coronary microcirculation
The ability of the coronary microcirculation to adapt to changing 
demands is vital. Coronary flow reserve is the maximum flow result-
ing from stress vasodilatation of coronary arteries and the coronary 
microcirculation, measured using positron emission tomography or 
magnetic resonance imaging. In this context, 90% of myocardial 
blood flow takes place through vessels with diameter <150 µm, 
which penetrate the walls of the myocardium.57 Coronary flow re-
serve is, therefore, a test of both endothelial dysfunction and coro-
nary microvascular reserve. It is expressed as the ratio of hyperemic 
to basal diastolic peak velocities, with a value above two considered 
normal. Low coronary flow reserve indicates a reduced ability to ap-
propriately increase flow in response to increased oxygen demand. 
Coronary flow reserve has been found to be significantly lower in 
dialysis patients compared with healthy controls who were well 
matched for age, sex, BMI, and blood pressure.39,58 In patients with 
angiographically normal coronary arteries, 50% of the dialysis co-
hort were found to have coronary flow reserve <2 compared with 
only 5% in the control group of non-dialysis patients.39
4  | POTENTIAL CONFOUNDING FAC TORS
Caution must be exercised in attributing all the alterations observed 
in the above studies to renal failure and its treatments. Many pa-
tients with end-stage kidney disease have co-morbid illnesses which 
may also affect the systemic microcirculation, most notably hy-
pertension, and diabetes mellitus. Several of the studies discussed 
above exclude from their control group of “healthy volunteers” those 
F I G U R E  3   Schematic representation of iontophoretic delivery of vasoactive substances. Iontophoresis delivers charged pharmacological 
agents in solution to a localized area of skin by applying an opposing electrical current. Laser Doppler technology in combination with 
iontophoretic application of vasoactive substances to the skin allows study of aspects of the vasodilatory capacity of dermal vessels. 
Traditionally, ACh and SNP are used to provoke endothelium-dependant and endothelium-independent vasodilation, respectively51
F I G U R E  4   Acquisition of SDF images. Hand held microscopes 
use side-stream dark field imaging to produce high-contrast real-
time videos of the sublingual vessels
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with these conditions but hypertension, diabetes, and other co-mor-
bidities are present in a large proportion of the dialysis group.32,36 
In these studies, measured differences between groups are likely to 
represent the combined effects of chronic uremia, dialysis, and other 
co-morbidities.
Even in otherwise well matched cohorts, dialysis patients fre-
quently have increased systolic blood pressure compared with their 
control counterparts.32,33 Therefore, in addition to their dialysis pa-
tients and healthy controls, Farkas and colleagues studied a third 
group of age-matched patients with essential hypertension.28 They 
were able to demonstrate a significant reduction in both endotheli-
um-dependant and independent vasodilatation in their dialysis pa-
tients compared with controls and those with hypertension.
5  | ARE MICROCIRCUL ATORY CHANGES 
A SSOCIATED WITH CLINIC AL OUTCOMES?
A link between microvascular dysfunction and adverse cardiovas-
cular outcomes has been demonstrated in other populations.3,4,59,60 
Vascular dysfunction in the skin has been demonstrated to correlate 
with coronary disease61 and be an independent marker for cardio-
vascular disease in patients with Type 2 diabetes.62 As these tech-
niques become better understood and increasingly used in renal 
cohorts, interest has turned to how they may be used as biomarkers 
to identify high risk patients and facilitate intervention at an earlier 
stage.
Coronary microvascular rarefaction has been postulated as con-
tributory to sudden cardiac death in the dialysis population.63 In a 
cohort study of nearly 4000 individuals encompassing the whole 
spectrum of chronic renal disease, coronary flow reserve was shown 
to be strongly associated with cardiovascular death independent of 
chronic renal disease stage.64 Adjusting for coronary flow reserve in 
chronic renal disease 4,5 and dialysis-dependant groups attenuated 
their risk of cardiovascular death by 10%, supporting the concept 
that coronary microvascular dysfunction may underlie some of the 
increased mortality associated with chronic renal disease.
In separate multi-variate regression analyses, microvascular im-
pairment as measured by forearm post-ischemic vasodilatation65 
and coronary flow reserve63 were found to be independently associ-
ated with all-cause mortality in hemodialysis patients.
Microvascular dysfunction of the coronary and peripheral circu-
lations has also been correlated with outcome measures known to 
have negative prognostic implications such as hypoalbuminemia66,67 
and right ventricular dysfunction.68
Chronic renal disease mineral bone disease can cause large 
vessel calcification, a strong predictor of cardiovascular death in 
hemodialysis patients.69 There is some evidence for an association 
between large vessel calcification and microvascular dysfunction 
in hemodialysis patients, those with femoral artery calcification ex-
hibited lower maximal vasodilatory responses to ACh and SNP than 
both controls and hemodialysis patients without large vessel calcifi-
cation.34 There is also increasing evidence of a relationship between 
markers of worsening chronic renal disease mineral bone disease 
and microvascular abnormalities in the absence of large vessel cal-
cification. Dermal capillary rarefaction and impaired coronary flow 
reserve have been associated with increasing levels of both iPTH33 
and phosphorous43,64 in chronic renal disease cohorts. Even in co-
horts with normal renal function, serum phosphate concentrations 
have been negatively correlated with post-occlusive capillary re-
cruitment70 and endothelial dysfunction in larger vessels.71
Patients at risk of other non-cardiovascular disease outcomes 
which significantly impact on morbidity and quality of life, such as 
wound healing have also been identified using these techniques. 
Those patients with lower skin blood flow both before and during 
hemodialysis, as measured by laser Doppler, have been shown to be 
at greater risk of developing wounds and skin defects.66 All patients 
in this study who later went on to develop a skin defect had evi-
dence of intradialytic “critical perfusion” at the microvascular level 
in at least one measured area, although none exhibited intradialytic 
hypotension.
6  | WHAT ARE THE EFFEC TS OF CHRONIC 
DIALYSIS?
Cardiovascular risk increases as patients progress through the stages 
of chronic renal disease (classified as stages 1–5 with progressive 
falls in glomerular filtration rate and increasing albuminuria) and with 
time on dialysis.72 Is microvascular impairment similarly related to 
stage of chronic renal disease and time on dialysis?
It has been found that even the creation of an arteriovenous 
fistula in preparation for hemodialysis may have systemic micro-
vascular effects. In pre-dialysis patients, successful formation of an 
arteriovenous fistula led to a reduction in endothelial-dependant 
F I G U R E  5   Example of sublingual microcirculation as visualized 
using SDF imaging. SDF is based on the principle that scattered 
green light is absorbed by hemoglobin in RBCs; therefore, any 
vessels containing RBCs can be visualized using this technique. 
These images can be used to assess; vessel density, perfusion 
indices, and heterogeneity45,46
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vasodilation in the fistula arm. Following fistula creation, these pa-
tients also exhibited a reduction in non-endothelium-dependant va-
sodilation in the contralateral arm, indicating that localized changes 
to the structure of the macrocirculation can lead to widespread 
changes in the microcirculation. This was in contrast to those pa-
tients who had primary arteriovenous fistula failure, who exhibited 
no recordable local or systemic changes.73
Cross-sectional studies also provide evidence for a relationship 
between stage of kidney disease and microcirculatory dysfunction. 
Plasma levels of shed glycocalyx components such as syndecan-1 
and markers of endothelial activation such as angiopoietin-2 cor-
relate inversely with eGFR.38 Retinal microvessels also narrow pro-
gressively with each stage of chronic kidney disease.74 Additionally, 
histopathological evidence of endothelial activation and infiltration 
by inflammatory cells in dermal capillaries40,41 and circulating levels 
of adhesion molecules such as sVCAM-1 correlate with duration of 
dialysis.75 The potential effects of renal replacement therapy itself 
on the microcirculation remain less well defined. Using SDF technol-
ogy, Dane and his colleagues were able to demonstrate impaired gly-
cocalyx integrity associated with worsening eGFR. However, in their 
end-stage renal disease group (n = 23) no statistically significant dif-
ference was seen between the dialysis patients (n = 9) and patients 
with end-stage renal disease who were not on dialysis (n = 14).38 
Common to many of the studies presented here small sample size 
may have contributed to the lack of statistically significant findings.
A large American cohort study found that although coronary 
microvascular function assessed by coronary flow reserve was 23% 
lower in dialysis patients compared with controls with preserved kid-
ney function, this reduction occurred early in chronic kidney disease, 
with a nadir being reached in chronic renal disease stage 4.64 The 
authors found no additional reductions in stage 5 or 5D. However, it 
is important to note that the chronic kidney disease stage 4 patients 
were on average 10 years older than the dialysis group and had a 
higher incidence of known ischemic heart disease and oral nitrate 
use. It is possible in light of this that survivor bias has limited the ap-
parent extent of microvascular dysfunction detected in the patients 
with chronic kidney disease stage 5 in this retrospective study. Some 
of these issues could be addressed by longitudinal studies directly 
investigating microvascular function in dialysis cohorts. INTHEMO 
is an ongoing 2-year study primarily designed to assess the effects 
of hemodialysis intensity on micro and macrovascular parameters.76 
In a preliminary report, these investigators found no statistically 
significant change in glycocalyx parameters at 6 months follow-up 
compared with baseline. They did, however, note significant het-
erogeneity in the degree and direction of change of calculated gly-
cocalyx properties at 6 months, and data at study completion are 
awaited. One important limitation of historical studies may be the 
effect of the hemodialysis procedure itself. The microcirculation is 
inherently dynamic, and as described below, timing of microvascular 
measurements with regards to the patients hemodynamic therapy 
itself may have significant impact on results. Standardization of tim-
ing of measurements with respect to hemodialysis therapy is an im-
portant consideration for future studies.
7  | WHAT ARE THE ACUTE EFFEC TS OF 
DIALYSIS?
Hemodialysis has been shown to cause varying degrees of macro-
hemodynamic instability in patients often because of ultrafiltration 
of fluid, observed clinically as intradialytic hypotension. Recurrent 
intradialytic hypotension is considered to have negative prognostic 
implications.77 Studies of the sublingual microcirculation using SDF 
during a single hemodialysis session have demonstrated a reduction 
in microvascular flow and decrease in the proportion of the micro-
circulation that is perfused through the course of the treatment.78,79 
This reduced flow in all microvessels has been attributed to a re-
duction in circulating volume secondary to ultrafiltration. In some 
studies, reduced microvascular perfusion has been demonstrated in 
patients undergoing isolated ultrafiltration but not in those under-
going hemodialysis with linear ultrafiltration.80 This finding is sup-
ported by data showing the reduced flow may be partially corrected 
by a maneuver designed to increase central venous filling.78 These 
microcirculatory changes were independent of macrohemodynamic 
changes, for example, blood pressure, implying an element of com-
pensation by the microcirculation.
Decreased intradialytic perfusion has also been demonstrated in 
the peripheral circulation.66,81 However, it has been suggested that 
changes in perfusion here may be dependent on the patient's pre-di-
alysis volume status. Hypervolemic patients who were ultrafiltrated 
to normovolemia had improved skin perfusion,82 this was accompa-
nied by a decrease in arterial and venous pressure and proposed to 
be as a result of decreased myogenic response as a local auto regu-
latory effect. Another potential mechanism could be interstitial fluid 
removal with reduced external compression of vessels.
Significant alterations in hemodynamics and shear stress result 
in stimuli noxious to the glycocalyx including oxidative stress83 and 
inflammation.84 An increase in plasma shed glycocalyx constituents 
has been demonstrated over the course of a 4 hour dialysis session. 
However, this was not accompanied by a deterioration in sublingual 
glycocalyx parameters, potentially reflecting differential responses 
to hemodialysis in different vascular beds.85 Importantly, the reli-
ability of plasma shed endothelial components as a marker of endo-
thelial damage in patients with significant renal impairment has been 
challenged, due to decreased renal excretion and unknown dialysis 
clearance.86
It has been suggested that hemodialysis may not be entirely 
detrimental to the microcirculation. The process of hemodialysis re-
sults in the release of local vasodilatory substances87 and removal 
of circulating inhibitors of endothelial function such as; asymmetri-
cal dimethylarginine, an inhibitor of endothelial NO production.88,89 
Improvements in retinal microvascular function during single he-
modialysis sessions have been demonstrated in several studies.90,91 
However, these potentially beneficial effects appear to be transient, 
returning to baseline within hours.88,92 This may, however, help to 
explain some of the heterogeneity in the literature and highlights the 
importance of timing of investigations with regards dialysis therapy 
when designing and evaluating data in studies of the microcirculation.
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8  | IS MICROCIRCUL ATORY 
DYSFUNC TION MODIFIABLE?
As there is evidence of a relationship between microcirculatory func-
tion and eGFR38,41 it could be postulated that successful restoration 
of excretory function should improve microcirculatory parameters. 
Renal transplantation is the preferred mode of renal replacement 
therapy for all eligible patients as cardiovascular outcomes and qual-
ity of life are improved compared with dialysis.
Early skin biopsy studies indicated that “uremia associated mi-
croangiopathy” could be at least partially reversed by successful 
transplantation.93 Using data and samples from a large biobank, 
a retrospective study of patients receiving their first renal trans-
plant having previously been on dialysis, found that sVCAM-1 
levels (a marker of endothelial injury) fell within 1 month of trans-
plantation and continued to decline for at least 2 years75 support-
ing an improvement in endothelial function with improvement in 
renal function.
Cross-sectional studies using SDF imaging in the sublingual cir-
culation have demonstrated significant deterioration in glycocalyx 
and microvascular perfusion parameters in dialysis patients com-
pared to age-matched healthy controls and renal transplant recip-
ients.32,38 At a median of 5 years post-transplant, the glycocalyx 
parameters of patients with a stable functioning transplant were 
indistinguishable from the healthy controls.38 While microvascular 
flow was more heterogeneous in transplant recipients, the total 
density of small vessels and the proportion that were perfused 
was not significantly worse than controls.32 In the coronary micro-
circulation, transplant recipients were found to have a significantly 
reduced coronary flow reserve compared with healthy controls 
(1.89 “v” 2.65), but better than a group of age-matched hemodial-
ysis patients (1.57).58
In those with a failing or failed transplant, the relationship ap-
pears to be more complex. Transplant recipients with evidence of 
interstitial fibrosis and tubular atrophy had sublingual glycocalyx pa-
rameters comparable to hemodialysis patients despite their median 
eGFR of 22 mL/min.38 Furthermore, patients who return to dialy-
sis after a failed transplant exhibited worse coronary microvascu-
lar function than dialysis (both hemodialysis and peritoneal dialysis) 
patients of similar vintage who have never been transplanted.67,94 
The known association between inflammation and microvascular 
dysfunction76 led the authors to speculate that inflammation asso-
ciated with the failed allograft was partially responsible for the de-
terioration, in both these studies the failed transplant recipients had 
higher inflammatory markers than the transplant naïve group. This is 
an interesting hypothesis although the underlying pathology is likely 
to be multifaceted. While time on dialysis may have been similar be-
tween groups the patients with failed transplant are likely to have 
had a longer period with end-stage renal failure, additionally they 
will have been exposed to immunosuppressant medications such as 
calcineurin inhibitors, with known vascular effects.95 As discussed 
above, changes to the microcirculation occur throughout the stages 
of chronic renal disease and what is not clear from this study is how 
changes in the failing transplant group compare to patients with a 
native eGFR of 22 mL/min.
9  | ISSUES IN THE CURRENT LITER ATURE
Comparison of studies in this area is impeded by methodological is-
sues. By its nature the microcirculation exhibits significant temporal 
and spatial heterogeneity.81 Consequently, most of the techniques 
outlined above have to contend with substantial intra-subject varia-
bility. Much of the literature reviewed here is cross-sectional; there-
fore, there will be significant variability in the outcome measures, 
reducing their ability to detect small differences between patient 
groups for example.
There are other experimental issues pertinent to studying a 
renal cohort. End-stage renal disease is a phenotype, not a specific 
pathology and therefore renal cohorts are also heterogeneous. 
Secular, geographic, and ethnic variation impact prevalent primary 
and co-morbid pathologies, many of which have direct relevance to 
the microcirculation such as diabetes and hypertension. There is also 
high usage in this population of medications known to impact micro-
vascular reactivity.
Studying patients undergoing an intermittent therapy, such as 
hemodialysis, presents its own challenges; as outlined above, timing 
of investigations is important, this varies both between and within 
studies.36 Rapidly changing flow and hematocrit, changes in room 
and dialysate temperature, different compositions of dialysate and 
method of vascular access are all likely to affect the results of these 
non-invasive techniques. Perhaps more importantly, such a hemody-
namic insult is likely to affect each vascular bed differently.
These inherent methodological issues are often compounded by 
small sample sizes.
10  | POTENTIAL FUTURE WORK
The issues identified above mean several gaps remain in our 
knowledge with regards the state of the microcirculation as meas-
ured using these non-invasive techniques. What is required to 
adequately delineate the natural history of microvascular dysfunc-
tion in chronic kidney disease and dialysis are large-scale, longitu-
dinal studies in a variety of vascular beds with consensus on timing 
of investigations.
Along with the heterogeneous nature of a renal cohort there are 
also several treatment options available for renal replacement ther-
apy. The two main forms of dialysis offered to patients, hemodialysis 
and peritoneal dialysis, are intrinsically different and likely to affect 
the systemic microcirculation in distinct ways. As a result of its acute 
hemodynamic effects and by virtue of the fact that they account 
for the large majority of the dialysis population, most microvascu-
lar work in dialysis patients has, to date, focused on hemodialysis. 
Studies investigating microcirculatory properties in peritoneal dial-
ysis patients lag behind their hemodialysis contemporaries. When 
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peritoneal dialysis patients are included in cohorts they are often an-
alyzed with the hemodialysis patients under the umbrella of “dialysis 
requiring”. Attempts to analyze them as a sub-group are undermined 
by small numbers.27
Peritoneal dialysis has been demonstrated to have cardiovascular 
effects18 but they are both qualitatively and quantitatively different 
from those of hemodialysis. There are also other challenges unique 
to peritoneal dialysis which need examining, most notably the effect 
of absorbed glucose. There is a body of work examining the effects 
of peritoneal dialysis fluid variants on macrohemodynamic measures 
such as blood pressure and cardiac output.87,96,97 Similar work exam-
ining effects on the microcirculation could allow intervention at an 
earlier stage in the pathological process. The functionality of peri-
toneal dialysis is largely dependent on the structure and integrity of 
the peritoneal microcirculation. Are there insights to be gained from 
the systemic microcirculation that may increase understanding and 
aid preservation of the peritoneal circulation?42,98
Despite these gaps in knowledge there is increasing evidence of 
microcirculatory dysfunction in dialysis cohorts that precedes large 
vessel disease and is associated with morbidity and mortality. This 
dysfunction appears to be the result of multiple insults including; 
uremia and its consequences, that is, chronic renal disease, mineral 
bone disease; co-morbid pathologies such as hypertension and dia-
betes and renal replacement therapy itself. This should emphasize 
to the clinician the importance of primary preventative strategies 
already enshrined in clinical practice such as dialysis adequacy tar-
gets, stringent blood pressure control, and correction of bone min-
eral abnormalities. Greater insights into the pathophysiology of 
microvascular dysfunction in these patients could advance clinical 
care of dialysis patients in several ways. It could improve our un-
derstanding of the potential benefits of commonly used medications 
such as ACE inhibitors, routinely used in proteinuric renal disease, 
there is evidence for a protective effect on systemic vascular en-
dothelium in animal models of aging99 and heart failure.100 It could 
help us understand how best to administer renal replacement ther-
apies; for example, the potential benefits of more “extended” he-
modialysis.76 It could also aid development of more novel therapies 
aimed at protecting endothelial function such as eNOS transcriptase 
enhancers.101
11  | CONCLUSION
The importance of the microcirculation in systemic diseases is be-
coming increasingly apparent. Historically, study of the microcir-
culation in patients with renal disease especially those on dialysis 
has lagged behind other chronic conditions. Difficulties in studying 
a heterogeneous patient group on intermittent therapies may have 
contributed to this disparity.
Studies have been small and largely cross-sectional. More tra-
ditional techniques for studying the microcirculation were often 
cumbersome and time consuming reducing their clinical utility. We 
are now gaining greater understanding of the role of newer, more 
patient friendly techniques such as SDF imaging which should allow 
expansion of participant numbers.
Reproducible differences in microvascular structure and ab-
normal function have been demonstrated in multiple vascular beds 
in dialysis patients compared with controls. The exact nature and 
chronology of these changes are yet to be fully defined.
As we anticipate an ever-expanding chronic renal disease pop-
ulation with its disproportionate cardiovascular burden, a greater 
understanding of this dysfunction becomes increasingly important. 
Large-scale longitudinal studies are required to achieve this with the 
hope that the knowledge gained will guide future interventions to 
abrogate cardiovascular risk for these patients.
PERSPEC TIVE
The importance of the systemic microcirculation in renal disease is 
increasingly appreciated. A growing body of work using non- invasive, 
in vivo techniques is expanding our knowledge of the nature and 
chronology of microvascular dysfunction. Future work should focus 
on whether early intervention in the pathological process will reduce 
cardiovascular risk.
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